Cargando…

Clinical implications of changes in hepatic drug metabolism in older people

Prescribing for older people is challenging because of the paucity of clinical trial evidence of therapeutic benefit in this population and the presence of evidence that older people are at increased risk of adverse drug reactions. The outcomes of pharmacotherapies in older people depend on age-rela...

Descripción completa

Detalles Bibliográficos
Autores principales: Hilmer, Sarah N, Shenfield, Gillian M, Le Couteur, David G
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1661619/
https://www.ncbi.nlm.nih.gov/pubmed/18360554
_version_ 1782131051462656000
author Hilmer, Sarah N
Shenfield, Gillian M
Le Couteur, David G
author_facet Hilmer, Sarah N
Shenfield, Gillian M
Le Couteur, David G
author_sort Hilmer, Sarah N
collection PubMed
description Prescribing for older people is challenging because of the paucity of clinical trial evidence of therapeutic benefit in this population and the presence of evidence that older people are at increased risk of adverse drug reactions. The outcomes of pharmacotherapies in older people depend on age-related changes in both pharmacokinetics and pharmacodynamics. Of the pharmacokinetic changes, those in hepatic metabolism are the most significant. Recent advances in biogerontology have improved our understanding of changes that occur in hepatic pharmacokinetics in older people. Knowledge of age-related changes in hepatic metabolism can guide prescribing and help reduce the risk–benefit ratio of using medications in older people.
format Text
id pubmed-1661619
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-16616192008-03-21 Clinical implications of changes in hepatic drug metabolism in older people Hilmer, Sarah N Shenfield, Gillian M Le Couteur, David G Ther Clin Risk Manag Review Prescribing for older people is challenging because of the paucity of clinical trial evidence of therapeutic benefit in this population and the presence of evidence that older people are at increased risk of adverse drug reactions. The outcomes of pharmacotherapies in older people depend on age-related changes in both pharmacokinetics and pharmacodynamics. Of the pharmacokinetic changes, those in hepatic metabolism are the most significant. Recent advances in biogerontology have improved our understanding of changes that occur in hepatic pharmacokinetics in older people. Knowledge of age-related changes in hepatic metabolism can guide prescribing and help reduce the risk–benefit ratio of using medications in older people. Dove Medical Press 2005-06 2005-06 /pmc/articles/PMC1661619/ /pubmed/18360554 Text en © 2005 Dove Medical Press Limited. All rights reserved
spellingShingle Review
Hilmer, Sarah N
Shenfield, Gillian M
Le Couteur, David G
Clinical implications of changes in hepatic drug metabolism in older people
title Clinical implications of changes in hepatic drug metabolism in older people
title_full Clinical implications of changes in hepatic drug metabolism in older people
title_fullStr Clinical implications of changes in hepatic drug metabolism in older people
title_full_unstemmed Clinical implications of changes in hepatic drug metabolism in older people
title_short Clinical implications of changes in hepatic drug metabolism in older people
title_sort clinical implications of changes in hepatic drug metabolism in older people
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1661619/
https://www.ncbi.nlm.nih.gov/pubmed/18360554
work_keys_str_mv AT hilmersarahn clinicalimplicationsofchangesinhepaticdrugmetabolisminolderpeople
AT shenfieldgillianm clinicalimplicationsofchangesinhepaticdrugmetabolisminolderpeople
AT lecouteurdavidg clinicalimplicationsofchangesinhepaticdrugmetabolisminolderpeople